Oncolytics Biotech Inc. (ONCY)
NASDAQ: ONCY · Real-Time Price · USD
1.040
+0.105 (11.23%)
At close: May 29, 2026, 4:00 PM EDT
1.050
+0.010 (0.96%)
After-hours: May 29, 2026, 5:33 PM EDT
Oncolytics Biotech Employees
Oncolytics Biotech had 29 employees as of December 31, 2025. The number of employees increased by 1 or 3.57% compared to the previous year.
Employees
29
Change (1Y)
1
Growth (1Y)
3.57%
Revenue / Employee
n/a
Profits / Employee
-$1,147,966
Market Cap
120.77M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 29 | 1 | 3.57% |
| Dec 31, 2024 | 28 | -1 | -3.45% |
| Dec 31, 2022 | 29 | 3 | 11.54% |
| Dec 31, 2021 | 26 | 1 | 4.00% |
| Dec 31, 2020 | 25 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Seer, Inc. | 124 |
| Cibus | 118 |
| Inovio Pharmaceuticals | 112 |
| Verrica Pharmaceuticals | 76 |
| Pyxis Oncology | 56 |
| PepGen | 56 |
| Vivani Medical | 42 |
| Cognition Therapeutics | 14 |
ONCY News
- 7 days ago - Oncolytics Biotech to present data at ASCO 2026 on pelareorep - TheFly
- 7 days ago - Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep's Potential Across Gastrointestinal Tumors - GlobeNewsWire
- 15 days ago - Oncolytics Biotech Quarterly report: Q1 2026 - Filings
- 25 days ago - Oncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer - GlobeNewsWire
- 4 weeks ago - Oncolytics says in alignment with FDA following pelareorep Type C meeting - TheFly
- 4 weeks ago - Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study - GlobeNewsWire
- 4 weeks ago - Oncolytics Biotech Slides: Corporate presentation - Filings
- 7 weeks ago - Oncolytics price target lowered to $5 from $7 at Lake Street - TheFly